Inhibrx Financial Statements From 2010 to 2022

INBX -  USA Stock  

USD 23.20  1.79  7.16%

Inhibrx financial statements provide useful quarterly and yearly information to potential Inhibrx investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Inhibrx financial statements helps investors assess Inhibrx's valuation, profitability, and current liquidity needs.
We have found sixty available fundamental trends for Inhibrx, which can be analyzed and compared to other ratios and to its competitors. Make sure you confirm all of Inhibrx regular market performance against the performance between 2010 and 2022 to make sure the company can sustain itself down the road.
Inhibrx Tangible Asset Value is fairly stable at the moment as compared to the past year. Inhibrx reported Tangible Asset Value of 165.3 Million in 2021. Working Capital is likely to rise to about 125 M in 2022, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (61.1 M) in 2022.

Inhibrx Financial Statements 

 
Refresh
Check Inhibrx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inhibrx main balance sheet or income statement drivers, such as Gross Profit of 14.5 M, Interest Expense of 10 M or Net Income to Non Controlling Interests of 127.1 K, as well as many exotic indicators such as Asset Turnover of 0.14, Book Value per Share of 3.71 or Current Ratio of 5.22. Inhibrx financial statements analysis is a perfect complement when working with Inhibrx Valuation or Volatility modules. It can also supplement various Inhibrx Technical models. Please see the analysis of Inhibrx Correlation against competitors.

Inhibrx Revenues

14.5 MillionShare

Inhibrx Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets178.4 M165.3 M46.4 M
Increasing
Slightly volatile
Cash and Equivalents159.6 M148 M35.9 M
Increasing
Slightly volatile
Deferred Revenue4.5 M3.4 M7.8 M
Decreasing
Slightly volatile
Property Plant and Equipment Net11.6 M13 M5.4 M
Increasing
Slightly volatile
Trade and Non Trade Receivables535.9 K553.5 K642.5 K
Decreasing
Slightly volatile
Trade and Non Trade Payables12.6 M15.5 MM
Increasing
Slightly volatile
Total Liabilities70.1 M78.5 M35.3 M
Increasing
Slightly volatile
Shareholders Equity93.6 M86.8 M(27.4 M)
Increasing
Slightly volatile
Current Assets164 M152 M39.6 M
Increasing
Slightly volatile
Assets Non Current12.2 M13.3 M6.7 M
Increasing
Slightly volatile
Current Liabilities32.2 M36.1 M20.5 M
Increasing
Slightly volatile
Liabilities Non Current37.9 M42.4 M14.8 M
Increasing
Slightly volatile
Total Debt39.8 M43.1 M19 M
Increasing
Slightly volatile
Debt Current1.4 M1.4 M4.8 M
Decreasing
Slightly volatile
Debt Non Current36.5 M41.3 M14.1 M
Increasing
Slightly volatile
Shareholders Equity USD93.6 M86.8 M(27.4 M)
Increasing
Slightly volatile
Cash and Equivalents USD159.6 M148 M35.9 M
Increasing
Slightly volatile
Total Debt USD39.8 M43.1 M19 M
Increasing
Slightly volatile

Inhibrx Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues14.5 M14.8 M10.2 M
Increasing
Slightly volatile
Selling General and Administrative Expense7.6 M7.9 M5.4 M
Increasing
Slightly volatile
Research and Development Expense74.4 M84.5 M44.7 M
Increasing
Slightly volatile
Operating Expenses82.5 M92.4 M50.4 M
Increasing
Slightly volatile
Interest Expense10 M12.4 MM
Increasing
Slightly volatile
Income Tax Expense2.8 K2.7 K136.2 K
Increasing
Very volatile
Net Income to Non Controlling Interests127.1 K127.8 K139.8 K
Decreasing
Slightly volatile
Weighted Average Shares27.2 M29.1 M20.2 M
Increasing
Slightly volatile
Weighted Average Shares Diluted27.2 M29.1 M20.2 M
Increasing
Slightly volatile
Revenues USD14.5 M14.8 M10.2 M
Increasing
Slightly volatile
Gross Profit14.5 M14.8 M10.2 M
Increasing
Slightly volatile

Inhibrx Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow from Financing206.5 M191.4 M55.9 M
Increasing
Slightly volatile
Issuance Repayment of Debt Securities 37.8 M46.7 M8.3 M
Increasing
Slightly volatile
Issuance Purchase of Equity Shares122.5 M123.2 M134.7 M
Decreasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents145.3 M134.7 M23.4 M
Increasing
Slightly volatile
Share Based Compensation5.3 M5.8 M3.3 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion2.5 M2.8 M1.3 M
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Return on Average Equity7.739.672.5084
Increasing
Slightly volatile
Gross Margin0.890.90.9842
Decreasing
Slightly volatile
Asset Turnover0.140.140.5902
Decreasing
Slightly volatile
Sales per Share0.640.590.5175
Increasing
Slightly volatile
Price to Sales Ratio57.8258.1663.6026
Decreasing
Slightly volatile
Price to Book Value14.7414.8316.2143
Decreasing
Slightly volatile
Debt to Equity Ratio1.121.04(0.0555)
Increasing
Slightly volatile
Current Ratio5.224.841.3982
Increasing
Slightly volatile
Book Value per Share3.713.44(1.8147)
Increasing
Slightly volatile
Tangible Assets Book Value per Share7.066.541.9767
Increasing
Slightly volatile

Inhibrx Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Capitalization1.1 B1.1 B1.2 B
Decreasing
Slightly volatile
Enterprise ValueBB1.1 B
Decreasing
Slightly volatile
Invested Capital24.1 M24.3 M8.9 M
Increasing
Slightly volatile
Average Assets81.4 M97.9 M34.4 M
Increasing
Slightly volatile
Invested Capital Average31 M32.9 M21.5 M
Increasing
Slightly volatile
Tangible Asset Value178.4 M165.3 M46.4 M
Increasing
Slightly volatile
Working Capital125 M115.9 M18.6 M
Increasing
Slightly volatile

Inhibrx Fundamental Market Drivers

Short Percent Of Float3.04%
Forward Price Earnings-9.39
Shares Short Prior Month641.4k
Average Daily Volume Last 10 Day426.7k
Average Daily Volume In Three Month253.86k
Date Short Interest15th of December 2021
Fifty Day Average38.32
Two Hundred Day Average30.98

Inhibrx Upcoming Events

Upcoming Quarterly Report11th of March 2022
Next Earnings Report12th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End11th of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

About Inhibrx Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Inhibrx income statement, its balance sheet, and the statement of cash flows. Inhibrx investors use historical funamental indicators, such as Inhibrx's revenue or net income, to determine how well the company is positioned to perform in the future. Although Inhibrx investors may use each financial statement separately, they are all related. The changes in Inhibrx's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Inhibrx's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Inhibrx Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Inhibrx. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Deferred Revenue3.4 M4.5 M
Revenues14.8 M14.5 M
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Inhibrx, Inc. was founded in 2010 and is headquartered in La Jolla, California. Inhibrx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 84 people.

Inhibrx Investors Sentiment

The influence of Inhibrx's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Inhibrx. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Inhibrx in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Inhibrx's short interest history, or implied volatility extrapolated from Inhibrx options trading.

Current Sentiment - INBX

Inhibrx Investor Sentiment

Macroaxis portfolio users are indifferent in their judgment towards investing in Inhibrx. What is your judgment towards investing in Inhibrx? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Inhibrx using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Inhibrx Correlation against competitors. Note that the Inhibrx information on this page should be used as a complementary analysis to other Inhibrx's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Complementary Tools for Inhibrx Stock analysis

When running Inhibrx price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Is Inhibrx's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inhibrx. If investors know Inhibrx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inhibrx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Inhibrx is measured differently than its book value, which is the value of Inhibrx that is recorded on the company's balance sheet. Investors also form their own opinion of Inhibrx's value that differs from its market value or its book value, called intrinsic value, which is Inhibrx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inhibrx's market value can be influenced by many factors that don't directly affect Inhibrx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inhibrx's value and its price as these two are different measures arrived at by different means. Investors typically determine Inhibrx value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inhibrx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.